Biodexa Advances eRapa for FAP Following FDA Feedback

Biodexa Pharmaceuticals is making strides in the fight against familial adenomatous polyposis (FAP) after receiving valuable guidance from the U.S. Food and Drug Administration (FDA). The company, following a productive Type C meeting, has now outlined a clear plan for its pivotal Phase 3 trial of eRapa. With no approved treatments for FAP, this trial represents a crucial step toward addressing an unmet medical need. The study, involving 168 patients across the U.S. and Europe, will be backed by a $17 million grant from the Cancer Prevention Research Institute of Texas, along with additional company funding.

Dr. Gary Shangold, Chief Medical Officer at Biodexa, expressed confidence in the trial’s future, highlighting the FDA’s support in refining key aspects such as the composite endpoint and statistical framework. With regulatory hurdles now cleared, Biodexa is gearing up for patient recruitment in the coming months. Conducted in collaboration with LumaBridge and Precision for Medicine LLC, the study aims to bring hope to those affected by FAP by providing a much-needed therapeutic option.